Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Leukemia Research
|
January 1, 1989
Evidence for a factor in normal human serum that induces human neutrophilic granulocyte end-stage maturation in vitro
W H Evans, S M Wilson, J M Bednarek, et al.
Cancer Research
|
October 15, 1988
Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512)
R B Weiss, R F Greene, R D Knight, et al.
Journal of Molecular and Cellular Cardiology
|
October 2, 2003
Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes
A Chanalaris, K M Lawrence, A Stephanou, et al.
Archives of Internal Medicine
|
September 12, 1994
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
R Gucalp, R Theriault, I Gill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2004
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
S A Schey, P Fields, J B Bartlett, et al.
Cancer
|
March 4, 2000
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials
A Lipton, R L Theriault, G N Hortobagyi, et al.
Journal of Clinical Pharmacology
|
April 1, 1997
Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
J R Berenson, L Rosen, R Vescio, et al.
The New England Journal of Medicine
|
December 12, 1996
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group
G N Hortobagyi, R L Theriault, L Porter, et al.
Leukemia
|
October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Leukemia
|
December 10, 2015
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Leukemia Research
|
January 1, 1989
Evidence for a factor in normal human serum that induces human neutrophilic granulocyte end-stage maturation in vitro
W H Evans, S M Wilson, J M Bednarek, et al.
Cancer Research
|
October 15, 1988
Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512)
R B Weiss, R F Greene, R D Knight, et al.
Journal of Molecular and Cellular Cardiology
|
October 2, 2003
Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes
A Chanalaris, K M Lawrence, A Stephanou, et al.
Archives of Internal Medicine
|
September 12, 1994
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
R Gucalp, R Theriault, I Gill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2004
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
S A Schey, P Fields, J B Bartlett, et al.
Cancer
|
March 4, 2000
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials
A Lipton, R L Theriault, G N Hortobagyi, et al.
Journal of Clinical Pharmacology
|
April 1, 1997
Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
J R Berenson, L Rosen, R Vescio, et al.
The New England Journal of Medicine
|
December 12, 1996
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group
G N Hortobagyi, R L Theriault, L Porter, et al.
Leukemia
|
October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Leukemia
|
December 10, 2015
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A F List, J M Bennett, M A Sekeres, et al.
Page
of 6